Skip to main content
Journal cover image

Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.

Publication ,  Journal Article
Johnson, LS; Benz, AP; Shoamanesh, A; Eikelboom, JW; Ezekowitz, M; Giugliano, RP; Wallentin, L; Ruff, CT; Lopes, RD; Jolly, S; Whitlock, R ...
Published in: J Am Heart Assoc
September 3, 2024

BACKGROUND: Despite oral anticoagulation, patients with atrial fibrillation (AF) remain at risk of ischemic stroke and systemic embolism (SE) events. For patients whose residual risk is sufficiently high, additional therapies might be useful to mitigate stroke risk. METHODS AND RESULTS: Individual patient data from 5 landmark trials testing oral anticoagulation in AF were pooled in A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in AF (COMBINE AF). We calculated the rate of ischemic stroke/SE among oral anticoagulation-treated patients with a CHA2DS2-VASc score≥2, across strata of CHA2DS2-VASc score, stroke history, and AF type, as either paroxysmal or nonparoxysmal. We included 71 794 patients with AF (median age 72 years, interquartile range, 13 years, 61.3% male) randomized to a direct oral anticoagulant or vitamin K antagonist, and followed for a mean of 2.1 (±0.8) years. The median CHA2DS2-VASc score was 4 (interquartile range, 3-5), 18.8% had a prior stroke, and 76.4% had nonparoxysmal AF. The overall rate of stroke/SE was 1.33%/y (95% CI, 1.27-1.39); 1.38%/y (95% CI, 1.31-1.45) for nonparoxysmal AF, and 1.15%/y (95% CI, 1.05-1.27) for paroxysmal AF. The rate of ischemic stroke/SE increased by a rate ratio of 1.36 (95% CI, 1.32-1.41) per 1-point increase in CHA2DS2-VASc, reaching 1.67%/y (95% CI, 1.59-1.75) ≥4 CHA2DS2-VASc points. Patients with both nonparoxysmal AF and CHA2DS2-VASc ≥4 had a stroke/SE rate of 1.75%/y (95% CI, 1.66-1.85). In patients with a prior stroke, the risk was 2.51%/y (95% CI, 2.33-2.71). CONCLUSIONS: AF type, CHA2DS2-VASc score, and stroke history can identify patients with AF, who despite oral anticoagulation have a residual stroke/SE risk of 1.5% to 2.5% per year. Evaluation of additional stroke/SE prevention strategies in high-risk patients is warranted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

September 3, 2024

Volume

13

Issue

17

Start / End Page

e034758

Location

England

Related Subject Headings

  • Risk Factors
  • Risk Assessment
  • Randomized Controlled Trials as Topic
  • Middle Aged
  • Male
  • Ischemic Stroke
  • Humans
  • Female
  • Atrial Fibrillation
  • Anticoagulants
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Johnson, L. S., Benz, A. P., Shoamanesh, A., Eikelboom, J. W., Ezekowitz, M., Giugliano, R. P., … Healey, J. S. (2024). Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF. J Am Heart Assoc, 13(17), e034758. https://doi.org/10.1161/JAHA.123.034758
Johnson, Linda S., Alexander P. Benz, Ashkan Shoamanesh, John W. Eikelboom, Michael Ezekowitz, Robert P. Giugliano, Lars Wallentin, et al. “Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.J Am Heart Assoc 13, no. 17 (September 3, 2024): e034758. https://doi.org/10.1161/JAHA.123.034758.
Johnson LS, Benz AP, Shoamanesh A, Eikelboom JW, Ezekowitz M, Giugliano RP, et al. Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF. J Am Heart Assoc. 2024 Sep 3;13(17):e034758.
Johnson, Linda S., et al. “Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF.J Am Heart Assoc, vol. 13, no. 17, Sept. 2024, p. e034758. Pubmed, doi:10.1161/JAHA.123.034758.
Johnson LS, Benz AP, Shoamanesh A, Eikelboom JW, Ezekowitz M, Giugliano RP, Wallentin L, Ruff CT, Lopes RD, Jolly S, Whitlock R, Granger CB, Connolly S, Healey JS. Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF. J Am Heart Assoc. 2024 Sep 3;13(17):e034758.
Journal cover image

Published In

J Am Heart Assoc

DOI

EISSN

2047-9980

Publication Date

September 3, 2024

Volume

13

Issue

17

Start / End Page

e034758

Location

England

Related Subject Headings

  • Risk Factors
  • Risk Assessment
  • Randomized Controlled Trials as Topic
  • Middle Aged
  • Male
  • Ischemic Stroke
  • Humans
  • Female
  • Atrial Fibrillation
  • Anticoagulants